ALK-Abello A/S/€ALKB
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About ALK-Abello A/S
ALK-Abelló A/S is a Danish company specializing in the development and production of allergy immunotherapy products. The company operates within the pharmaceutical industry, providing allergy treatments that include tablets, injections, and drops. Notably, ALK-Abelló focuses on allergy immunotherapy for respiratory allergies, such as allergies to grass, tree pollen, house dust mites, and animal dander. Headquartered in Hørsholm, Denmark, ALK-Abelló serves a global market with a significant presence in Europe and North America. The company's strategic focus on research and development in allergy solutions and its specialized product portfolio underscore its commitment to addressing a critical niche in the healthcare sector.
Ticker
€ALKB
Sector
Primary listing
XGAT
Employees
2,782
Headquarters
Hørsholm, Denmark
Website
ALK-Abello A/S Metrics
BasicAdvanced
€6.1B
46.33
€0.60
0.59
-
Price and volume
Market cap
€6.1B
Beta
0.59
52-week high
€28.10
52-week low
€17.49
Average daily volume
80K
Financial strength
Current ratio
2.242
Quick ratio
1.047
Long term debt to equity
7.098
Total debt to equity
10.125
Interest coverage (TTM)
16.20%
Profitability
EBITDA (TTM)
208.576
Gross margin (TTM)
65.06%
Net profit margin (TTM)
17.04%
Operating margin (TTM)
23.22%
Effective tax rate (TTM)
23.27%
Revenue per employee (TTM)
€282,650
Management effectiveness
Return on assets (TTM)
11.11%
Return on equity (TTM)
18.56%
Valuation
Price to earnings (TTM)
46.326
Price to revenue (TTM)
7.89
Price to book
7.83
Price to tangible book (TTM)
11.31
Price to free cash flow (TTM)
660.656
Free cash flow yield (TTM)
0.15%
Free cash flow per share (TTM)
0.042
Growth
Revenue change (TTM)
13.15%
Earnings per share change (TTM)
39.26%
3-year revenue growth (CAGR)
11.51%
10-year revenue growth (CAGR)
9.57%
3-year earnings per share growth (CAGR)
46.86%
10-year earnings per share growth (CAGR)
17.11%
Bulls say / Bears say
ALK-Abelló delivered 12% organic revenue growth in Q2 2025, while operating profit rose 41% with EBIT margin expanding to 25% versus 19% a year ago, demonstrating strong operational leverage
Full-year 2025 revenue guidance was upgraded to 12–14% growth in local currencies (from 9–13%), reflecting confidence in sustained demand across Europe and North America
Tablet sales climbed 16% year-on-year to DKK 831 million in Q2, driven by volume growth with European sales up 17% and North American sales up 32%, underscoring leadership in the allergy tablet market
ALK withdrew its biologics licence application for the house dust mite sublingual tablet in China, delaying potential market entry in what is anticipated to become the world’s largest HDM AIT market
Tablet stocking in Europe fell from Q1, signalling potential volatility in inventory builds and future growth momentum despite maintained underlying volume trends
Management plans to allocate additional funds to strategic growth investments in H2, which could weigh on near-term cash flows and EBIT margin improvements
Data summarised monthly by Lightyear AI. Last updated on 5 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ALK-Abello A/S stock?
ALK-Abello A/S (ALKB) has a market cap of €6.1B as of September 17, 2025.
What is the P/E ratio for ALK-Abello A/S stock?
The price to earnings (P/E) ratio for ALK-Abello A/S (ALKB) stock is 46.33 as of September 17, 2025.
Does ALK-Abello A/S stock pay dividends?
No, ALK-Abello A/S (ALKB) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next ALK-Abello A/S dividend payment date?
ALK-Abello A/S (ALKB) stock does not pay dividends to its shareholders.
What is the beta indicator for ALK-Abello A/S?
ALK-Abello A/S (ALKB) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.